Who founded Clostrabio?

Clostrabio was founded by Jeffrey Hubbell, Cathryn Nagler in 2016.

Who are Clostrabio's investors?

Clostrabio's investors include Portal Innovations, Stone Mountain Ventures.

How much funding has Clostrabio raised?

Clostrabio has disclosed $9.9M raised across 1 round.

Where is Clostrabio headquartered?

Clostrabio is headquartered in Chicago, US.

Clostrabio

Chicago, US · Founded 2016 · Delaware corporation · 13 employees on LinkedIn · 2 known investors

Find your way into Clostrabio

409 people in our graph share verified history with the Clostrabio team — schools, employers, funds. One of them is your warm intro.

Erin Mooreunlockedknows Cathryn Nagler · together at Massachusetts General Hospital (overlapped)

×3knows the team · via Massachusetts General Hospital

×2knows the team · via Harvard Medical School

knows the team · via University of Chicago

×3knows the team · via Barnard College

×2knows the team · via NYU Grossman School of Medicine

ClostraBio develops next-generation probiotics and a platform for delivering bacterial metabolites to support gut health, targeting inflammatory bowel disease (IBD) and food allergy. Its lead product, CLB101 (Anaerostipes caccae), is a probiotic aimed at supporting gut barrier function, immunity, and microbiome balance, offered both as a dietary supplement and a therapeutic delivery platform.

Biotech Digital Health Healthtech

Founders & leadership

Clostrabio was founded in 2016 by Jeffrey Hubbell and Cathryn Nagler.

Jeffrey HubbellSecretary

Cathryn Nagler inCo-FounderShe has spent a decade researching how the commensal microbiota regulates immune responses to food antigens, work conducted through antibiotic-treated and gnotobiotic mouse models, and is now translating these findings into microbiome-modulating therapeutic development.

Brett NewswangerChief Operating Officer

Board

John Flavin inExecutive ChairmanGeneral Partner at Portal Innovations Momentum

Investors · 2

Portal InnovationsChicago

Stone Mountain VenturesDallas · $5Mvia John Diaz · inferred

Reported raises · per SEC filings

Form D private placements

$9.9M disclosed across 1 round · 2022

▶$9.9MraisedSep 2022 · 15 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Brett NewswangerExecutive Officer
Jeffrey HubbellExecutive Officer, Director
Cathryn NaglerExecutive Officer, Director
John FlavinExecutive Officer, Director

Offering amount: $11M
Amount sold: $9.9M
First sale: Sep 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bridgebio6 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

Companies competing with Clostrabio for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Clostrabio do?: ClostraBio develops next-generation probiotics and a platform for delivering bacterial metabolites to support gut health, targeting inflammatory bowel disease (IBD) and food allergy. Its lead product, CLB101 (Anaerostipes caccae), is a probiotic aimed at supporting gut barrier function, immunity, and microbiome balance, offered both as a dietary supplement and a therapeutic delivery platform.
Who founded Clostrabio?: Clostrabio was founded by Jeffrey Hubbell, Cathryn Nagler in 2016.
Who are Clostrabio's investors?: Clostrabio's investors include Portal Innovations, Stone Mountain Ventures.
How much funding has Clostrabio raised?: Clostrabio has disclosed $9.9M raised across 1 round.
Where is Clostrabio headquartered?: Clostrabio is headquartered in Chicago, US.